Phocas Financial Corp’s Denali Therapeutics DNLI Stock Holding History

Phocas Financial Corp’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Buy	+71,197	New	+$1.46M	0.25%	117

Other funds holding DNLI

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

KOCAA

Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Phocas Financial Corp's DNLI Position: Q2 2026 in Review

Phocas Financial Corp opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 71,197 shares worth $1.83M. The stake represents 0.25% of the portfolio and ranks #117 among its holdings.

60 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Phocas Financial Corp held 71,197 shares of Denali Therapeutics worth $1.83M as of Q2 2026.
Denali Therapeutics was a new Phocas Financial Corp position in Q2 2026.
Denali Therapeutics made up 0.25% of Phocas Financial Corp's portfolio in Q2 2026, its #117 holding.
60 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.